Organogenesis is a regenerative medicine company that develops, manufactures, and sells advanced wound care and surgical and sports medicine products designed to address chronic and acute wounds as well as tendon and ligament injuries. The company's core products include bioengineered skin substitutes such as Apligraf and Dermagraft, along with placental-based allografts and other wound repair matrices, which are sold to hospitals, wound care centers, ambulatory surgery centers, and physician offices primarily in the United States. Revenue is generated through product sales reimbursed by Medicare, Medicaid, and private payers based on regulatory clearance status and clinical application, supported by an in-house sales force and network of independent agencies along with dedicated reimbursement and medical support services.